Slide 1: FY26 Financial Results & Operational Update
(ASX: AYA) FY26 Financial Results & Operational Update FINANCIAL YEAR ENDED 30 JUNE 2026 Scaling the Future John Konstantopoulos, CEO & Co-Founder of Heart Care Clayton Hatch, CFO 01 September 2026 ARTRYA FY2026 FINANCIAL RESULTS & OPERATIONAL UPDATE
Slide 2: Important Notice
Important Notice IMPORTANT NOTICE AND DISCLAIMER These presentation materials have been prepared by Artrya Limited (Artrya or Company). By receiving the Presentation The Presentation Materials contain summary information about the Company and its activities which is current as at the date Materials,
Slide 3: Our Purpose is to save lives through faster and more accurate detection of coronary artery disease
Our Purpose is to save lives through faster and more accurate detection of coronary artery disease 3 ARTRYA FY2026 FINANCIAL RESULTS & OPERATIONAL UPDATE
Slide 4: Artrya – AI technology platform for coronary artery disease
Artrya – AI technology platform for coronary artery disease Salix® is the only real-time, point of care platform globally improving patient care and streamlining workflow • More people die from heart disease than all cancers combined2 1 Global health issue • Every 40 seconds in the U.S., someone suf
Slide 5: Results & Highlights
Results & Highlights Financial Year ended 30 June 2026 5 ARTRYA FY2026 FINANCIAL RESULTS & OPERATIONAL UPDATE
Slide 6: 2026 Highlights & Achievements
2026 Highlights & Achievements This year we successfully executed our commercial launch – enabling us to grow revenues and deliver scale into the future 3 U.S. customers SAPPHIRE Study U.S. Customer secured launched Success Team Tanner Health, Cone Health, 6 major U.S. healthcare systems Supporting
Slide 7: Financial Summary – FY2026
Financial Summary – FY2026 Commercial revenue base established in FY26, with minimum contracted revenue secured across three foundation customers Cash1 $74.0m Debt1 Nil 1 2 3 4 5 6 Contracts = Deployment / Clinical Use Payer Pre- Claim Cash Market cap2 Signed Integration Begins Authorisation Adjudic
Slide 8: CCTA is transforming how coronary artery disease is diagnosed
CCTA is transforming how coronary artery disease is diagnosed CT-first adoption has shifted the bottleneck downstream CAD is deadly CCTA is becoming the More complete One scan. Many insights view of CAD and common front-line test ANATOMY Where is the disease? 1 in 3 Plaque die from How much disease?
Slide 9: Adoption of CCTA is outpacing the ability of Hospital Systems to respond
Adoption of CCTA is outpacing the ability of Hospital Systems to respond CT-first adoption is accelerating faster than hospital capacity can absorb Rising Demand Health System Constraints • Guideline shifts: CCTA is now first-line for chest pain • Growing volumes: scan volumes are growing faster tha
Slide 10: Salix®: The Operating Platform for Cardiac CT
Salix®: The Operating Platform for Cardiac CT Clear clinical insights into actionable decisions in minutes One Reporting Platform for CAD Centralised CCTA reporting, analysis, and workflow. Reduces physician fatigue and reporting costs More Clinical Capacity Improved efficiency and care, transforms
Slide 11: From off-site workflows to 10-minute decision
From off-site workflows to 10-minute decision Salix® fits directly into the existing clinical workflow; no portals, no off-site vendors Onsite - Manual CCTA Assessment Offsite – ‘Human in the loop’ Currently Current • Inefficient CCTA Visualisation Software Clinician workflow approach Clinician Rece
Slide 12: Salix® patients have Symptomatic or Acute chest pain
Salix® patients have Symptomatic or Acute chest pain U.S. treatment guidelines specify patients with CCTA who require coronary plaque and / or flow analysis No Plaque Detected on CCTA¹ (~30% of CCTAs) No CAD Plaque 1-39% Stenosis Analysis Symptomatic CCTA Salix® Patients with Performed Platform Plaq
Slide 13: Salix® Revenue model - a single platform solution built for scale
Salix® Revenue model - a single platform solution built for scale Attractive revenue model of subscription and fees per scan - analysing CCTA scans for coronary artery disease Increasing clinical utility and revenue opportunity2 Salix® Coronary Flow Final validation stage - FDA clearance targeted by
Slide 14: Go-to-Market Strategy
Go-to-Market Strategy Focus on Foundation Customers and SAPPHIRE 14 ARTRYA FY2026 FINANCIAL RESULTS & OPERATIONAL UPDATE
Slide 15: 2026 commercial launch - Go to Market strategy
2026 commercial launch - Go to Market strategy Our three-part commercial strategy is focused and clear to deliver value 01 02 03 Foundation Customers SAPPHIRE Study Key Opinion Leaders Partner with early adopters to Conduct a targeted clinical study Mobilise influential clinicians to validate commer
Slide 16: U.S. Foundation partners converted to commercial customers
U.S. Foundation partners converted to commercial customers Successful deployment of Salix® in the first U.S. hospital systems 5 hospitals fully integrated • Non-profit health system serving communities across west Georgia and east Alabama • Network spanning 5 hospitals, 5 cardiovascular centres, S
Slide 17: First U.S. Customer – Tanner Health
First U.S. Customer – Tanner Health Significant cardiologist reporting time savings demonstrated in U.S. clinical use Seamless deployment Single platform – Ease of Use Deployed across clinical, imaging, EMR and Ease of use of a single platform, single portal is a key cybersecurity systems driver to
Slide 18: Commercial footprint to support leading health systems
Commercial footprint to support leading health systems Foundation customers, SAPPHIRE sites, and our Atlanta support pod working together to drive U.S. growth 1 MASS. GENERAL BRIGHAM 5 HCA HEALTHCARE 7 CONE HEALTH Massachusetts HQ: Nashville North Carolina 12 hospitals – Across the U.S. 5 hospitals
Slide 19: Flagship Novel Plaque Study – SAPPHIRE underway
Flagship Novel Plaque Study – SAPPHIRE underway Validating the novel Salix® Plaque Dispersion Score to identify patients at risk of heart attack Overview Key Phases Key Benefits • Evaluate Salix® Plaque Dispersion Score assessing cardiovascular risk PHASE 1 1 Predict future adverse events • Specific
Slide 20: Building Ethical & Sustainable Growth
Building Ethical & Sustainable Growth Artrya continues to develop its ESG framework and disclosures guided by four main pillars 1 Environmental sustainability Reducing our environmental impact through sustainable operations and responsible innovation 37% 40% Female Diversity & board Inclusion Ensuri
Slide 21: Building commercial momentum
Building commercial momentum A clear path forward 21 ARTRYA FY2026 FINANCIAL RESULTS & OPERATIONAL UPDATE
Slide 22: Our strategy is to build revenues within our hospital clients
Our strategy is to build revenues within our hospital clients Our strategy is to build revenues within our hospital clients We aim to create value as we shift from initial deployment to increasing usage and revenues Platform expansion Product expansion 2 Revenue per site 1 Clinical validation Workfl
Slide 23: Artrya Valuation Potential
Our pathway to creating future value for shareholders Our pathway to creating future value for shareholders Clearly identified value inflection points that drive towards repeatable adoption and a scaled Salix® platform Scaled platform Commercial execution will shift Repeatable Widespread adoption, 1
Slide 24: Artrya’s moat extends well beyond the AI model
Artrya’s moat extends well beyond the AI model Artrya’s competitive advantage is built across four reinforcing pillars – each harder to replicate and strengthening with scale 1 One Integrated Platform 2 Real-Time, Point-of-Care Delivery ~8–10 minute automated analysis delivered within the Anatomy +
Slide 25: Roadmap for FY27: Scaling Salix® in the U.S.
Roadmap for FY27: Scaling Salix® in the U.S. Building the foundation for sustainable commercial growth through revenue, clinical validation, and operational readiness Increase scan volumes and recurring revenue across all foundation customers Drive Adoption Clinical Build & Scale Commercial Revenues
Slide 26: Five Key Takeaways
Five Key Takeaways Salix® is the best-in-class solution enhancing clinician decision making and patient outcomes 1 Commercial launch established and positioned to scale — 3 multi-year U.S. customers contracted 2 Salix® platform live in Tanner and NGHS and revenue generating – Cone Health deployment
Slide 27: Appendices
Appendices FY26 Financial Statements 27 ARTRYA FY2026 FINANCIAL RESULTS & OPERATIONAL UPDATE
Slide 28: Investment supporting U.S. commercialisation and final Coronary Flow validation
Investment supporting U.S. commercialisation and final Coronary Flow validation FY26 investment reflects deliberate expansion of U.S. commercial capability and completion of key product and regulatory programs A$’000 Note 2024 2025 2026 Revenue 0 28 177 Accounting adjustments 1 0 0 (149) 1• Revenues
Slide 29: Statutory accounts – FY26
Statutory accounts – FY26 Profit & Loss 2024 2025 2026 Balance Sheet 2024 2025 2026 Revenue 0 28 28 Assets Other income 3,689 5,464 5,647 Current assets Cash and cash equivalents 7,134 11,332 44,025 Total income 3,689 5,492 5,675 Trade and other receivables 3,874 5,382 5,355 Contractors and consulta
Slide 30: Thank you
Thank you Corporate Enquiries Investor & Media Enquiries John Konstantopoulos David Allen or John Granger Co-Founder and Chief Executive Officer Hawkesbury Partners Tel: +61 8 6478 7816 Tel: +61 499 100 038 or +61 410 577 155 Email: contact@artrya.com Email: investors@artrya.com www.artrya.com 30 AR